Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday as Tech-Driven Gains Falter at Year-End

MT NewswiresDec 30, 2024 09:02 ET

BTIG Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62

Moomoo NewsDec 30, 2024 06:31 ET · Ratings

IDEAYA Biosciences Enters Into Licensing Agreement With Jiangsu Hengrui for Cancer Drug Candidate SHR-4849

MT NewswiresDec 30, 2024 04:34 ET

Reported Sunday, IDEAYA Biosciences Secures Global License For SHR-4849, A Novel Phase 1 DLL3-Targeting ADC For SCLC And NET Tumors

BenzingaDec 30, 2024 02:33 ET

IDEAYA Biosciences: Strategic Acquisition and Promising Clinical Data Drive Buy Recommendation

TipRanksDec 29, 2024 14:05 ET

IDEAYA Biosciences (IDYA): A Down Year Presents a Window of Opportunity for Investors

TipRanksDec 29, 2024 11:18 ET